Gipharma heads for EANM’14 with new strengths

news-releasesGipharma Srl
October 8th 2014

Saluggia, Italy: –Injectables small volume liquids, lyophilized parenterals and radiopharmaceuticals specialist Gipharma has announced it will be present at this month’s annual congress of the European Association of Nuclear Medicine, EANM’14, in Sweden.

Gipharma’s Commercial Director, Dr. Andrea Confetti, will represent the CMO in Gothenburg. He will be available for face-to-face meetingsfrom Sunday through to Tuesday (October 19-21).

“I am really looking forward to attending EANM this year,” said Mr. Confetti.

“This is a wonderful event for meeting old partners and making new ones and I’m confident to have many very interesting conversations about potential new projects,” he added.

New capabilities

“Gipharma has a very impressive range of capabilities to place on the table in any collaboration,” said Andrea Confetti.

“I’m sure our clients will be very interested to hear of the progress on our upgraded logistics. At our Saluggia site we are rapidly approaching completion of our new expanded warehouse for raw materials, primary packaging components and ancillary equipment, with environmental monitoring well underway. This will be the final link in enabling a smoother flow of materials to feed our two production lines,” Mr. Confetti added.

About Gipharma

Gipharma Srl is based in Saluggia, northwest Italy, where it operates as a pharmaceutical contract manufacturing organization (CMO) for small volume injectable liquids and freeze-dried powders (aseptic and terminally sterilized processes). The company typically handles small/medium-sized product batches ranging from 5.000 to 14.000 vials.

Gipharma specializes in oxygen-sensitive products such as radiopharmaceutical cold kits, for which it has a long-standing experience and supplies all leading imaging players in Europe. It also provides services for chemical and microbiological testing of drug products and can release drug product and investigational medicinal product (IMP) batches for Europe. Its expertise also extends out to support services in PET radiopharmaceutical manufacturing and testing.

Gipharma is fully owned by Advanced Accelerator Applications SA, an international specialist in Molecular Nuclear Medicine.

About EANM ’14

The 27th Annual Congress of the European Association of Nuclear Medicine, EANM ’14, is being held at the he Swedish Exhibition & Congress Center in Gothenburg from October 18 to October 22, 2014.

The congress focuses on nuclear medicine, which is fast developing in clinical as well as experimental medicine. The EANM meeting provides a diary highlight for the multidisciplinary community practicing in nuclear medicine, with plenary lectures devoted to NM therapy, hybrid imaging and molecular life sciences.

The 2014 congress features a list of eminent speakers, including Prof. Martin Jean Schlumberger, Prof. Piotr Slomka of UCLA, Dr. Markus Rudin from University of Zurich, Prof. Marion de Jong from Rotterdam, Netherlands and Prof. Koen van Laere from Leuven, Belgium.

For the first time, the congress will feature a Biology Track to promote high-quality research through interaction between basic and translational clinical scientists.

More information at http://eanm14.eanm.org/